ARENA PHARMACEUTICALS, INC.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$9.2M
Doctors Paid
11
Transactions
4,138
2024 Total
$594,052
Payment Breakdown by Category
Research$9.1M (99.2%)
Consulting$69,545 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.1M | 4,112 | 99.2% |
| Consulting Fee | $69,545 | 26 | 0.8% |
Payments by Type
Research
$9.1M
4,112 transactions
General
$69,545
26 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN ADULT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS | $2.6M | 0 | 618 |
| A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 24WEEK STUDY WITH A 28WEEK OPENLABEL EXTENSION TO ASSESS THE SAFETY AND EFFICACY OF ETRASIMOD IN SUBJECTS WITH MODERATETOSEVERE ALOPECIA AREATA | $1.3M | 0 | 553 |
| A MULTICENTER RANDOMIZED DOUBLEBLIND PARALLELGROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL ETRASIMOD AS INDUCTION AND MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | $975,727 | 0 | 288 |
| AN OPENLABEL EXTENSION STUDY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | $832,077 | 0 | 1,416 |
| A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS | $763,077 | 0 | 648 |
| A PHASE 23 RANDOMIZED MULTICENTER STUDY OF GBT021601 ADMINISTERED ORALLY TO PARTICIPANTS WITH SICKLE CELL DISEASE AND AN OPENLABEL PHARMACOKINETICS STUDY IN PEDIATRIC PARTICIPANTS WITH SICKLE CELL DISEASE | $729,582 | 0 | 88 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | $469,550 | 0 | 233 |
| AN OPENLABEL PHASE 1 STUDY TO EVALUATE DRUGDRUG INTERACTIONS OF AGENTS COADMINISTERED WITH ENCORAFENIB AND BINIMETINIB IN PATIENTS WITH BRAF V600MUTANT UNRESECTABLE OR METASTATIC MELANOMA OR OTHER ADVANCED SOLID TUMORS | $374,464 | 0 | 6 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 12WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | $371,037 | 0 | 171 |
| AN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | $324,512 | 0 | 20 |
| A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CROSSOVER STUDY TO ASSESS THE EFFECT OF ORAL TEMANOGREL ON DIGITAL BLOOD FLOW IN SUBJECTS WITH RAYNAUDS PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS | $220,967 | 0 | 47 |
| A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFECT ON MICROVASCULAR OBSTRUCTION OF TEMANOGREL IN SUBJECTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | $87,241 | 0 | 21 |
| A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP STUDY TO EVALUATE THE SAFETY TOLERABILITY AND EFFICACY OF OLORINAB IN SUBJECTS WITH IRRITABLE BOWEL SYNDROME EXPERIENCING ABDOMINAL PAIN | $4,218 | 0 | 2 |
| A PHASE2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLEDCROSSOVER STUDY TO ASSESS THE EFFECT OF ORAL TEMANOGREL ON DIGITAL BLOOD FLOW IN SUBJECTS WITH RAYNAUDS PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS | $1,800 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Anatomic Pathology & Clinical Pathology | $57,500 | 1 | $57,500 |
| Gastroenterology | $10,021 | 8 | $1,253 |
| Family Medicine | $1,524 | 1 | $1,524 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Reetesh Pai | Anatomic Pathology & Clinical Pathology | Palo Alto, CA | $57,500 | $0 |
| Bahram Ahmadi, Md, MD | Gastroenterology | Sebring, FL | $2,000 | $0 |
| Michael Chiorean, Md, MD | Gastroenterology | Issaquah, WA | $2,000 | $0 |
| Dr. Niaz Ausaf, Do, DO | Family Medicine | Sarasota, FL | $1,524 | $0 |
| Dr. Poonam Beniwal-Patel, M.d, M.D | Gastroenterology | Milwaukee, WI | $1,500 | $0 |
| Dr. Curtis Baum, Md, MD | Gastroenterology | Topeka, KS | $1,500 | $0 |
| Evan Dellon, M.d., M.p.h, M.D., M.P.H | Gastroenterology | Chapel Hill, NC | $1,496 | $0 |
| Loren Brook, M.d, M.D | Gastroenterology | Cincinnati, OH | $900.00 | $0 |
| Unknown Provider | — | — | $500.00 | $0 |
| Dr. Joshua Sloan, D.o, D.O | Gastroenterology | Minneapolis, MN | $450.00 | $0 |
| Larry Clark, M.d, M.D | Gastroenterology | Lynchburg, VA | $175.00 | $0 |
Ad
Top Products
- VELSIPITY $1.7M
- BRAFTOVI $374,464
Payment Categories
- Consulting $69,545
- Research $9.1M
About ARENA PHARMACEUTICALS, INC.
ARENA PHARMACEUTICALS, INC. has made $9.2M in payments to 11 healthcare providers, recorded across 4,138 transactions in the CMS Open Payments database. In 2024, the company paid $594,052. The top product by payment volume is VELSIPITY ($1.7M).
Payments were distributed across 3 medical specialties. The top specialty by payment amount is Anatomic Pathology & Clinical Pathology ($57,500 to 1 doctors).
Payment categories include: Consulting ($69,545), Research ($9.1M).